Keyword: Prexton Therapeutics
The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.
In our EuroBiotech roundup this week, Cellectis’ subsidiary set for IPO, Serono spinout starts phase 2 and Pfenex bags J&J milestone.
Prexton Therapeutics has raised €29 million ($31 million) to take its Parkinson’s disease candidate through two phase 2 trials.
Prexton Therapeutics has brought its Parkinson's program through a first-in-human trial, setting it up to start a Phase II study in the first half of next year.